Lv11
20 积分 2025-06-05 加入
Development of Chinese innovative drugs in the USA
5分钟前
待确认
The molecular blueprint of targeted radionuclide therapy
2小时前
已完结
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
1个月前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Somatostatin and Somatostatin Receptors
1个月前
已完结
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study
2个月前
已完结
Dansylated Amino Acid–Modified Long-Acting PSMA Derivatives68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics
2个月前
已完结
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
2个月前
已完结
Head-to-Head Comparison of 68Ga-PSMA-11 with 68Ga-P137 in Patients with Suspected Prostate Cancer
2个月前
已完结
99mTc-MIP-1404 SPECT/CT Companion Diagnostic for177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
2个月前
已关闭
皖公网安备34019202002308
